Heart and Blood Diseases

All Conditions

Musculoskeletal Diseases

Nutritional and Metabolic Diseases

Vascular Diseases

Bone Diseases

Bone Diseases, Metabolic

Metabolic Diseases

18 and older patients who undergo the conventional CT scan and the photon counting CT (PCCT) scan. Patient's images on the conventional scanner provide internal control to compare to the PCCT images.

Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.

PHOTON COUNTING CT Scanner

Elizabeth C Jones, M.D.

Using an investigational CT scanner which uses a new type of detector to capture X-rays, (a photon counting CT detector), the goal of this experimental study is to compare conventional CT images to CT images using the photon counting detector in patients undergoing CT scans for clinically indicated reasons. The main question it aims to answer is whether the images produced using the new detectors are superior in quality. Participants will undergo the clinically indicated CT images and the photon counting detector CT images of a limited area during the same examination time.

NIH develops new imaging techniques as one of its priorities for accelerating science, including methods for non-invasive patient assessments. Computed tomographic (CT) imaging is a mainstay of diagnostic imaging. The latest major technological advance is photon counting CT (PCCT) which uses a new x-ray detector that measures x-ray penetration of the body and the energy of each x-ray photon. NIH Clinical Center will use a prototype Siemens PCCT CounT systems built for clinical investigational use. The scanner can perform standard CT and PCCT imaging. In this protocol, NIH patients already enrolled in a clinical research protocol and who are referred to Radiology for diagnostic CT as part of that research may be enrolled in this study of PCCT. The diagnostic CT scan requested by their medical care team will be performed on the CounT scanner, providing the clinically indicated imaging, along with a single abbreviated PCCT exam of an organ or body part to support PCCT feasibility of the PCCT to provide better images in several small groups of patients with selected medical conditions. The data will be used to characterize quality of the PCCT images and to develop testable hypotheses and new diagnostic applications using PCCT capabilities.

Current CT systems, such as the Siemens SOMATOM Flash, have two x-ray tubes, each paired with an x-ray detector that measures total x-ray penetration of the patient and uses that information to create the images. The CounT scanner is a modified version of the Flash in which one of the two standard detectors has been replaced with a PCCT detector. The two imaging modes for the CounT scanner are (i) standard detector study as in a Flash scanner and (ii) PCCT scan. The patient scan will thus include clinically indicated radiation exposure with the standard detector and research radiation over a limited field with the PCCT detector. The CounT system is sited at the Clinical Center under a CRADA (Cooperative research and development agreement) with Siemens Medical Solutions.

Compared to current scanners, PCCT is expected to offer four major advantages:

* lower radiation dose
* greater spatial resolution
* reduced imaging noise
* x-ray energy discrimination

As a translational development protocol, all imaging studies are open-label and data may be analyzed as they are collected.

Enrolled patients may be scanned on the investigational Photon Counting CT scanner. Conventional images also obtained for comparison using the same scanner at the same time.

Translational Development of Photon-counting CT Imaging

Translational Development of Photon-Counting CT Imaging

Mean difference in relative image quality grading of CT images using Photon counting detectors vs. conventional detectors in group of patients with various clinical conditions. Scale name "Visual grading analysis (VGA)" . Expert radiologist observers compare the relative grades of the images from the PCCT to the grades of the same patient's reference images from conventional CT acquired at the same time. The visual grading scale incorporates technical factors in the acquisition and image display (such as contrast, noise and presence of artifacts and post processing). Grading is based on 5 point scale. 1- lowest image quality, 5- highest image quality. 5 is a better result. Scale as follows: 1 Images not usable- severe limitations for diagnostic use, 2 Limited -some loss of information, significant limitations for clinical use, 3 Adequate -moderate limitations for diagnostic use, 4 Good-minimal limitations for clinical use, 5 Excellent- no limitations for clinical diagnosis.

National Institutes of Health Clinical Center (CC)

Events related to the diagnostic CT component are not reported. Unexpected incidental findings may be visible on the diagnostic scan read immediately or possibly only visible only on the PCCT research images which would be reviewed within 24 hours.

57 participants, 56 individual patients. One patient was scanned twice. Each of the patient's scans was evaluated and counted as a participant.

PHOTON COUNTING CT: Enrolled patients will undergo the requested clinical diagnostic CT study on the PCCT system using the standard detector, with or without IV and/or oral contrast as indicated. They will also undergo a brief PCCT scan as part of the examination. The scan will thus include both clinically indicated radiation exposure with the standard detector and research radiation with the PCCT detector.

Patients Receiving the Intervention PCCT CT Scan

up to 750 male or female, 18 and older patients

PHOTON COUNTING CT: Enrolled patients will undergo the requested clinical diagnostic CT study on the PCCT system using the standard detector, with or without IV and/or oral contrast as indicated. They will also undergo a brief PCCT scan as part of the examination. The scan will thus include both clinically indicated radiation exposure with the standard detector and research radiation with the PCCT detector.

Patients Referred for Diagnostic CT Scans

Some patients were enrolled however were unable to receive the intervention of PCCT on the investigational CT scanner due to scanner downtime.

Age, Continuous

There were patients who were enrolled but were unable to undergo the intervention , PCCT CT scan due to scanner downtime.

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Patients must be adults over 18 years of age. referred for diagnostic CT based on order request in the EMR.

Adults referred for diagnostic CT scan

11 patients could not be scanned on the PCCT investigational scanner after being enrolled due to scanner downtime.

The PCCT detector and investigational CT scanner itself were in development at the time of the trial. The detector and scanner platform has been developed by industry since this time. These results are not predictive of the performance of the FDA approved PCCT scanner which was approved in October 2021.

Dr. Elizabeth Jones Chief, Radiology and Imaging Sciences

Enrolled patients referred or invited who will undergo their clinically indicated diagnostic CT study on the PCCT system using the standard detector. They will also undergo a PCCT scan on the system restricted in extent to an organ or body part as part of the examination.

Patients Enrolled in Protocol

Patients with various conditions including cancer who underwent their routine conventional CT scan with additional PCCT images obtained for comparison.

Mean Difference in Diagnostic Image Quality Grading of Photon Counting CT vs Conventional CT Images.

67 enrolled participants

PHOTON COUNTING CT: Enrolled patients that could not undergo the requested clinical diagnostic CT study on the PCCT system using the standard detector, and the abbreviated PCCT scan as part of the examination. This occurred due to scheduling conflicts, and scanner down time failure to calibrate or other software Quality control failures. Patients received their CT exams on other conventional scanners and were removed from the protocol without the PCCT intervention.

For patients who underwent the investigational scan, they completed the protocol immediately following the scan.

Patients Enrolled to Receive the Intervention PCCT CT Scan

Overall Study

Immune System Diseases

Infections

Digestive System Diseases

Blood and Lymph Conditions

Symptoms and General Pathology

Autoimmune Diseases

Heart Diseases

Hepatitis A

Hepatitis C

Hepatitis

Hemostatic Disorders

Blood Coagulation Disorders

Inflammatory Bowel Diseases

Intestinal Diseases

Liver Diseases

Gastrointestinal Diseases

Communicable Diseases

Blood-Borne Infections

Hepatitis, Viral, Human

Virus Diseases

Flaviviridae Infections

RNA Virus Infections

Gastroenteritis

Hematologic Diseases

Hemorrhagic Disorders

Adults receiving health care at the University of Chicago Medical Center.

1200 Patients Project Study Team

Cancer Clinical Trials Office

Peter H O'Donnell, MD

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

University of Chicago

Patients subject to endocrine or digestive surgery will have intraoperative pCLE examination. The installation and surgical opening will be performed according to standard protocols. The contrast agent, fluorescein, will be injected intravenously to allow tissue visualization with pCLE. During the surgery, the surgeon will perform the pCLE examination, to obtain and record video sequences of in situ structures. Frozen sections will be obtained on the same samples and will further guide the surgical decision-making.

Histological examination by pCLE technique preceding the frozen section

pCLE

IV Fluorescein (fluorescent contrast agent) administration

IV fluorescein administration

Mihaela Ignat, MD, PhD

Intraoperative histological examination is a fundamental tool in surgery. Probe-based Confocal Laser Endomicroscopy (pCLE) is a new imaging technique which enables real-time, microscope-resolution imaging, currently used in endoscopy. This pilot study aims to evaluate pCLE in surgical setting. The objective is the depiction of histological rendering of normal and pathological tissues through pCLE. Feasibility of real-time diagnosis will also be assessed. All surgical conditions usually necessitating frozen section will be investigated. A total of 30 patients, with various pathology of the thyroid / parathyroid, stomach, esophagus, pancreas, adrenal, colon / small intestine, liver will be included. Diagnostic criteria will be defined by a surgeon - pathologist team and further validated by retrospective analysis of the video sequences in comparison to conventional histology slides. The data will be used to create an image bank of reference optical biopsy images. The study will allow to point out the surgical conditions in which pCLE is the most effective and reliable and could eventually replace the frozen section technique.

Intraoperative histological examination is a fundamental tool for cancer surgery (extent of surgery, resection margins, sentinel lymph node) and necessary in other circumstances like redo surgery or endocrine surgery. Using conventional frozen section technique results in the prolongation of operating time of about 40 minutes.

Probe-based Confocal Laser Endomicroscopy (pCLE) is a new imaging technique which enables real-time, microscope-resolution imaging. Specifically, after intravenous injection of a fluorescent contrast agent - in this study fluorescein will be used, the pCLE system provides video sequences of the tissue, using a confocal microscope integrated in a miniprobe and a low power laser as the illumination source (Cellvizio®, Mauna Kea Technologies, Paris, France).

The pCLE is currently used in endoscopy, mainly for the follow-up of Barrett's esophagus, colorectal polyps and strictures of the bile and pancreatic ducts, but also in urology. The pCLE has never been tested in open or video-assisted surgery settings. Sterilizable probes exist and are certified for use via an endoscope in France (UHD CystoFlexTM, AQ-FLEX 19TM Mauna Kea Technologies, Paris, France). A probe (CelioFlex UHDTM) is currently being developed for use in laparoscopic surgery setting.

This pilot study aims to evaluate pCLE in surgical setting. Each anatomical structure corresponds to a specific tissue architecture, which is today known through standard histological examination. Conventional histology implies alteration of the tissue architecture, with ablation of blood supply, sampling and technical treatment of the samples (fixation, cutting, staining). The pCLE enables to bypass this process and allows obtaining images of the microscopic structure in vivo, without cell damage and without interruption of the blood and lymphatic circulation. The obtained video sequences reflect the microscopic architecture, in a form which is to date, neither mapped nor exploited for deep organs. The potential of this technique was demonstrated in intraabdominal organs only in the animal model, with very encouraging results as the sensitivity and specificity of pCLE were superior to standard histological examination.

The primary objective is the depiction of histological rendering of normal and pathological tissues through pCLE. Feasibility of real-time diagnosis will also be assessed. All surgical conditions usually necessitating frozen section will be investigated. A total of 30 patients, with various pathology of the thyroid / parathyroid, stomach, esophagus, pancreas, adrenal, colon / small intestine, liver will be included.

The installation and surgical opening will be performed according to standard protocols. A contrast agent, fluorescein, will be injected intravenously to allow tissue visualization with the pCLE. During the surgery, the surgeon will perform the pCLE examination, to obtain and record video sequences of in situ structures. Frozen sections will be obtained on the same samples and will further guide the surgical decision-making.

Diagnostic criteria will be defined by a surgeon - pathologist team and further validated by retrospective analysis of the sequences in comparison to conventional histology slides. The data will be used to create an image bank of reference optical biopsy images.

The study will allow to point out the surgical conditions in which pCLE is the most effective and reliable and could eventually replace the frozen section technique.

A second study, in comparative prospective settings, could further be focused only on the promising conditions in order to evaluate diagnosis accuracy on a statistical basis.

Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study

Assessment of the Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery - a Pilot Study

The diagnosis proposed by the surgeon / investigator in intraoperative setting on the basis of video sequences of pCLE will be compared to frozen section.

The diagnosis proposed by the surgeon / investigator after retrospective review of the intraoperative video sequences of pCLE based on the newly described diagnosis criteria will be compared to frozen section and conventional histology.

Comparison of the surgeon's ability to obtain intraoperative diagnosis relative to that of the pathologist in the same circumstances.

Evaluation of the time required for the practice of pCLE and comparison to the time required for frozen section.

Morbidity rate / mortality specific to the pCLE imaging procedure.

IHU Strasbourg

Gland and Hormone Related Diseases

Behaviors and Mental Disorders

Nervous System Diseases

Rare Diseases

Coronary Artery Disease

Diabetes Mellitus

Syndrome

Chronic Disease

Depression

Depressive Disorder

Cognitive Dysfunction

Atherosclerosis

Pain

Ischemia

Myocardial Ischemia

Metabolic Syndrome

Death

Coronary Disease

Chronic Pain

Insulin Resistance

Hyperinsulinism

Glucose Metabolism Disorders

Arteriosclerosis

Arterial Occlusive Diseases

Disease Attributes

Cognition Disorders

Neurocognitive Disorders

Mental Disorders

Psychotic Disorders

Neurologic Manifestations

Chronic Graft Versus Host Disease

Jussi Kauhanen, MD, PhD

To determine associations between dietary factors and risk of major chronic diseases and their risk factors

STUDY POPULATION The Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD) is an on-going prospective, population-based cohort study of risk factors for cardiovascular diseases, other chronic diseases and metabolic conditions in a sample of men from eastern Finland. The baseline examinations were carried out between 1984 and 1989, when 2,682 men (82.9% of those eligible) who were 42, 48, 54 or 60 years old were recruited. The first cohort consisted of 1166 men who were 54 years old, enrolled in 1984-1986, and the second cohort included 1516 men who were 42, 48, 54 or 60 years old, enrolled in 1986-1989. The baseline examinations were followed by the 4-year examinations (1991-1993), in which 1038 men from the second cohort (88% of the eligible) participated. At the 11-year examinations (1998-2001), all men from the second cohort were invited and 854 men (95% of the eligible) participated. These examinations were also the baseline for 920 postmenopausal women (78.4% of the 1173 eligible women) from the same area, aged 53-73 years. During the 20-year examination round, all men from the first and second baseline cohorts and all women were invited to the study site, and a total of 1241 men (80% of the eligible) and 634 women (81.0%) participated.

ASSESSMENT OF DIETARY INTAKES Food consumption has been assessed with an instructed food recording of four days, one of which was a weekend day, by household measures. A picture book of common foods and dishes was used to help in estimation of portion sizes. For each food item the participant could choose from 3-5 commonly used portion sizes or describe the portion size in relation to those in the book. In order to further improve accuracy, instructions were given and completed food records were checked by a nutritionist together with a participant. Nutrient intakes were estimated using the NUTRICA® 2.5 software (Social Insurance Institution, Turku, Finland). The databank of the software is mainly based on Finnish values of nutrient composition of foods.

OUTCOME ASSESSMENT Registration of the incidence of major chronic diseases and deaths during the follow up is based on the national registries (Hospital discharge registry, Cause of death register, Social Insurance Institution of Finland register for reimbursement of medicine expenses) by use of the Finnish personal identification code (social security number), and/or on findings at the re-examination rounds (such as fasting plasma glucose or 2-h oral glucose tolerance test to define type 2 diabetes in addition to data from the national registries).

Blood, serum, plasma, urine, hair, nails, DNA

Kuopio Ischaemic Heart Disease Risk Factor Study (Nutrition Component)

Data available for collaborative projects

Progression of common carotid artery - intima-media thickness (CCA-IMT)

Incidence of hospitalization due infectious disease

University of Eastern Finland

Neoplasms

Multiple Sclerosis

Sclerosis

Myasthenia Gravis

Myelitis

Myelitis, Transverse

Demyelinating Autoimmune Diseases, CNS

Autoimmune Diseases of the Nervous System

Demyelinating Diseases

Paraneoplastic Syndromes

Paraneoplastic Syndromes, Nervous System

Nervous System Neoplasms

Neurodegenerative Diseases

Neuromuscular Junction Diseases

Neuromuscular Diseases

Central Nervous System Infections

Central Nervous System Diseases

Spinal Cord Diseases

Neuroinflammatory Diseases

Transverse Myelitis

All Drugs and Chemicals

Antibodies

Autoantibodies

Immunoglobulins

Subjects with multiple sclerosis and other autoimmune and inflammatory disease of the nervous system

A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.

Blood Draw

A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.

Cheek swab

David Richman, MD

Under normal conditions our immune system protects us against infections and tumors. The immune system does this by recognizing that the infecting organism or the tumor is foreign to the body and attacking it. One way the immune system attacks a foreign target is by making proteins called antibodies that bind to the target. Sometimes, for reasons we poorly understand, the immune system wrongly identifies part of our own body as being foreign and attacks it. This can result in disease such as some forms of diabetes and thyroid disease, as well as some neurological diseases. In this study, one tablespoon of blood will be removed from each subject and tested to see if the immune system is making antibodies against components of the nerves and muscles. We also hope to learn if these antibodies contribute to the development or worsening of illnesses of the nervous system. Only one blood draw is required, but subjects may be asked to give up to 8 additional blood samples to see if the level of antibodies changes over time. Any additional blood draws would be performed at regularly scheduled clinic visits. There would be at least 3 months between blood draws over a period of up to 3 years, if requested by the physician.

Depending on your diagnosis, the physician may also request the collection of mouth (buccal) cells. This takes about one minute and is painless. The cells are collected by swishing a swab around your mouth. This cheek swab would be done with each blood draw.

Please note that this study is conducted ONLY at UC Davis and that all participants must be seen in our clinic located in Sacramento, CA. Results of the testing performed in this study are not given to the participants. This study is not intended to treat or diagnose any condition.

The purposes of the study are to determine the frequency of auto-antibodies to 1) heat shock proteins and 2) to other molecules including cytoskeletal proteins such as rapsyn in diseases of the nervous system.

5cc of serum will be obtained from patients with multiple sclerosis and other autoimmune and inflammatory diseases of the nervous system including myasthenia gravis and transverse myelitis and from patients with other neurological diseases. Standard methodology to assure safe handling of serum will be used. Diluted serum will be tested for specific reactivity with heat shock proteins (Sigma Chemical Co., St. Louis, MO) as well as with other antigens in a standard ELISA as well as immunoblot.

Buccal swab will also be obtained in conjunction with each blood draw. Rapsyn and other cytoskeletal proteins will be extracted from Torpedo californica electric organ by means of differential centrifugation followed by alkali extraction. For the ELISA, a standard titration curve will be obtained for a positive control serum as previously determined. Negative control sera will be obtained from individuals with other degenerative neurological diseases. Titers of test serum will be determined as the dilution that generates a positive result that is two standard deviations from the mean of the background. Positive ELISA results will be confirmed by immunoblot. Patients may be tested at one time point only. If the serum is positive for specific antibody binding, additional serum samples may be obtained and retested up to 8 more times approximately 3 months apart. Correlation with severity of clinical findings and specific antibody titer will be made. Severity of clinical findings will be determined by the neurological exam done by the investigator.

5cc of serum will be obtained from patients with multiple sclerosis and other autoimmune and inflammatory diseases of the nervous system. Samples may be processed immediately or at a later time. Samples will be stored frozen in the freezer located in the Neuroscience building at Research Park in Davis, CA. Samples are identified with initials only.

Serum Auto-Antibodies in Neurological Diseases

CCRC: Serum Auto-Antibodies in Neurological Disease

University of California, Davis

Wounds and Injuries

Dementia

Hyperthermia

Fever

Vasculitis

Osteomyelitis

Fever of Unknown Origin

Bone Diseases, Infectious

Body Temperature Changes

Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.

positron emission tomography

computed tomography

magnetic resonance imaging

Pablo Ros, MD, MPH, PhD

This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with cancer, cardiac diseases, or neurologic diseases. PET-MRI combines two imaging methods that can be used to evaluate disease. PET-MRI is similar to standard-of-care PET-CT, but exposes the patient to less radiation. It is not yet known whether PET-MRI produces better image quality than PET-CT in diagnosing patients with cancer, cardiac disease, or neurologic disease.

PRIMARY OBJECTIVES:

I. To assess and optimize image quality of PET and MRI focusing on technical artifacts and their correction.

II. To assess the accuracy of PET quantification based on MR attenuation correction (MRAC) derived from various MRI sequences and reconstruction algorithms including the effect of routinely used Gadolinium-based contrast agents on MRAC.

III. To determine the clinical and diagnostic accuracy of PET-MRI in comparison to standard-of-care diagnostic imaging.

IV. To assess the efficacy and workflow in combining PET and MRI in one single examination as compared to separate imaging studies.

V. To assess the potential for radiation dose reduction if PET-CT is substituted by PET-MRI, thus avoiding the radiation exposure from the CT-component.

PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases

PET-MRI: Evaluation, Optimization and Clinical Implementation

Overall image quality scores obtained from the two imaging modalities will be compared with the hypothesis that hybrid PET-MRI images is as good as PET-CT images or superior (not inferior) to the PET-CT images. Evaluation of overall image quality will be assessed using the following criteria: 1=excellent, 2=good, 3=acceptable, 4=poor, 5=not acceptable. A Wilcoxon (Mann-Whitney) rank-sum test with a 0.100 significance level will be used.

Lesion based SUV will be estimated and compared for PET-MR and PET-CT images in normal organs and compared. A two-sided two-sample t-test will be used to show significance of difference.

A two-sided z-test will be used to detect the difference in the area under the curve showing the sensitivity, specificity, positive and negative predictive values as well as accuracy of diagnostic information.

Statistical difference in time between PET-MRI versus sequential approach for PET-CT plus MRI. Workflow with shortest timely efforts and sufficient diagnostic information will be established as routine procedure.

Dose measurements will be used to calculate effective radiation dose in each patient. Dose calculations of effective dose will be used to estimate dose savings in omitting the CT component of PET-CT. Statistical tests will use a 0.10 significance level and will be 2-sided

National Cancer Institute (NCI)

Case Comprehensive Cancer Center

Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.

positron emission tomography: Undergo PET

computed tomography: Undergo CT

magnetic resonance imaging: Undergo MRI

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Translational Development of Photon-counting CT Imaging	NCT03878134	Cancer Inflammatory Di... Vascular Diseas... Metabolic Bone ...	PHOTON COUNTING...	18 Years -	National Institutes of Health Clinical Center (CC)
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing	NCT01280825	Patients Underg... Heart Diseases Inflammatory Bo... Autoimmune Dise... Inflammatory Di... Blood Coagulati... Hepatitis C Non-Metastatic ...		18 Years -	University of Chicago
Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study	NCT02552004	All Surgical Co... Malignant Tumor Inflammatory Di... Benign Tumor	pCLE IV fluorescein ...	18 Years -	IHU Strasbourg
Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study	NCT02552004	All Surgical Co... Malignant Tumor Inflammatory Di... Benign Tumor	pCLE IV fluorescein ...	18 Years -	IHU Strasbourg
Kuopio Ischaemic Heart Disease Risk Factor Study (Nutrition Component)	NCT03221127	Cardiovascular ... Diabetes Metabolic Syndr... Cancer Inflammatory Di... Atherosclerosis Cognitive Decli... Liver Diseases Death Pain, Chronic Depression Infection Chronic Disease		42 Years - 73 Years	University of Eastern Finland
Serum Auto-Antibodies in Neurological Diseases	NCT00704626	Multiple Sclero... Myasthenia Grav... Transverse Myel...	Blood Draw Cheek swab	18 Years -	University of California, Davis
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases	NCT02084147	Cardiac Disease Dementia Inflammatory Di... Fever of Unknow... Vasculitis Osteomyelitis FDG Avid Cancer...	positron emissi... computed tomogr... magnetic resona...	18 Years -	Case Comprehensive Cancer Center
Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study	NCT02552004	All Surgical Co... Malignant Tumor Inflammatory Di... Benign Tumor	pCLE IV fluorescein ...	18 Years -	IHU Strasbourg

Spots Global Cancer Trial Database for inflammatory disease